热门资讯> 正文
PL 9643第三阶段测试更新后Paltin股价上涨8%
2024-08-29 03:21
- Palatin Technologies (NYSE:PTN) stock was up 8% in afternoon trading after the company announced the FDA has confirmed the acceptability of the protocols and endpoints for the remaining Phase 3 clinical studies for its drug candidate PL9643 in the treatment of dry eye disease.
- The company plans to run two Phase 3 studies, MELODY-2 and MELODY-3, with enrollment expected to begin in Q4.
- If the trials are successful, Palatin expects to be able to file for FDA approval in the first half of 2026.
More on Palatin Tech
- Palatin starts Phase 2 obesity study of bremelanotide with Zepbound
- Seeking Alpha’s Quant Rating on Palatin Tech
- Historical earnings data for Palatin Tech
- Financial information for Palatin Tech
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
